Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A3 | P38919 | 1/20 | 1.00 |
| ▸ | EIF4A1 | P60842 | 1/20 | 1.00 |
| ▸ | EIF4A2 | Q14240 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.42 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.42 |
| ▸ | EBP | Q15125 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epihippuristanol SCHEMBL21358104 | 1.00 | EIF4A3 (1.00) | EIF4A3EIF4A1EIF4A2KDM4ESLCO1B3 | |
| Epihippurin 1 SCHEMBL30088348 | 0.81 | EIF4A3 (0.68) | EIF4A3EIF4A1EIF4A2 | |
| SCHEMBL17790599 | 0.73 | EIF4A3 (0.56) | EIF4A3EIF4A1EIF4A2LMNACYP2C19 | |
| SCHEMBL17790603 | 0.73 | EIF4A3 (0.56) | EIF4A3EIF4A1EIF4A2LMNACYP2C19 | |
| SCHEMBL17790606 | 0.73 | EIF4A3 (0.56) | EIF4A3EIF4A1EIF4A2LMNACYP2C19 | |
| SCHEMBL17790604 | 0.73 | EIF4A3 (0.56) | EIF4A3EIF4A1EIF4A2LMNACYP2C19 | |
| SCHEMBL17790607 | 0.73 | EIF4A3 (0.56) | EIF4A3EIF4A1EIF4A2LMNACYP2C19 | |
| SCHEMBL17790601 | 0.73 | EIF4A3 (0.56) | EIF4A3EIF4A1EIF4A2LMNACYP2C19 | |
| SCHEMBL11438646 | 0.72 | EIF4A3 (0.56) | EIF4A3EIF4A1EIF4A2ALDH1A1LMNA | |
| SCHEMBL14416971 | 0.69 | LMNA (0.68) | EIF4A3EIF4A1EIF4A2LMNACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527764-B2 | Methods and compositions for treating androgen receptor deficient, androgen receptor low, and castration-resistant prostate cancers | FRED HUTCHINSON CANCER CENTER (US) | 2026-01-20 | — | — | US | claimed |
| US-20250255894-A1 | INHIBITORS OF EIF4A | Aceae Nutra Limited (GB) | 2025-08-14 | — | — | US | claimed |
| EP-4554571-A2 | EIF4A INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-21 | — | — | EP | claimed |
| WO-2025093619-A1 | BOOSTING CAP-INDEPENDENT TRANSLATION | CIRCIO AB (SE) | 2025-05-08 | — | — | WO | claimed |
| EP-4489763-A1 | INHIBITORS OF EIF4A | Aceae Nutra Limited (GB) | 2025-01-15 | — | — | EP | claimed |
| US-20240393340-A1 | PROGNOSIS AND PREDICTIVE BIOMARKERS AND BIOLOGICAL APPLICATIONS THEREOF | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-11-28 | — | — | US | claimed |
| US-20240277742-A1 | TRANSLATION INHIBITOR WITHOUT OCCUPYING RIBOSOME RESOURCES AS ANTI-TUMOR DRUG | CHI BIOTECH CO., LTD. (CN) | 2024-08-22 | — | — | US | claimed |
| WO-2024016000-A2 | EIF4A INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-18 | — | — | WO | claimed |
| WO-2023170413-A1 | INHIBITORS OF EIF4A | Aceae Nutra Limited (GB) | 2023-09-14 | — | — | WO | claimed |
| WO-2023138011-A1 | TRANSLATION INHIBITOR NOT OCCUPYING RIBOSOME RESOURCE AS ANTITUMOR DRUG | 深圳承启生物科技有限公司 | 2023-07-27 | — | — | WO | claimed |
| US-20150224132-A1 | COMPOSITIONS AND METHODS FOR TREATING FIBROTIC DISEASE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-08-13 | — | — | US | claimed |
| US-20150219624-A1 | METHODS FOR IDENTIFYING ANTI-CANCER COMPOUNDS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2015-08-06 | — | — | US | claimed |
| WO-2015085221-A2 | METHODS FOR IDENTIFYING ANTI-CANCER COMPOUNDS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2015-06-11 | — | — | WO | claimed |
| WO-2014184211-A1 | PROGNOSIS AND PREDICTIVE BIOMARKERS AND BIOLOGICAL APPLICATIONS THEREOF | INSTITUT GUSTAVE ROUSSY (FR) | 2014-11-20 | — | — | WO | claimed |
| US-20110288153-A1 | TRANSLATION FACTORS AS ANTI-AGING DRUG TARGETS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-24 | — | — | US | claimed |
| US-8008346-B2 | Chemotherapeutic agents for inhibition of protein translation | The Royal University for the Advancement of Learning/McGill University (CA) | 2011-08-30 | — | — | US | claimed |
| WO-2010059706-A2 | TRANSLATION FACTORS AS ANTI-AGING DRUG TARGETS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-27 | — | — | WO | claimed |
| CN-101476163-A | Use of RecQL4 gene high expression as novel target in antineoplastic medicament preparation | YONGLIANG ZHAO (CN) | 2009-07-08 | — | — | CN | claimed |
| US-20090118362-A1 | CHEMOTHERAPEUTIC AGENTS FOR INHIBITION OF PROTEIN TRANSLATION | THE ROYAL INSTITUTE FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2009-05-07 | — | — | US | claimed |
| WO-2007009264-A1 | CHEMOTHERAPEUTIC AGENTS FOR INHIBITION OF PROTEIN TRANSLATION | MCGILL UNIVERSITY (CA) | 2007-01-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527764-B2 | Methods and compositions for treating androgen receptor deficient, androgen receptor low, and castration-resistant prostate cancers | EIF4E, EIF4EBP1, EIF4A2 | EIF4A3 10/4885EIF4A1 5/4885EIF4A2 3/4885 |
| US-20240277742-A1 | TRANSLATION INHIBITOR WITHOUT OCCUPYING RIBOSOME RESOURCES AS ANTI-TUMOR DRUG | RACK1, RPL30, RRBP1 | EIF4A3 83/4885EIF4A1 36/4885EIF4A2 27/4885 |
| US-20090118362-A1 | CHEMOTHERAPEUTIC AGENTS FOR INHIBITION OF PROTEIN TRANSLATION | EIF4A1, EIF4A2, EIF4E | EIF4A3 5/4885EIF4A1 1/4885EIF4A2 2/4885 |
| US-20250255894-A1 | INHIBITORS OF EIF4A | EIF4A1, EIF4EBP1, EIF4E | EIF4A3 5/4885EIF4A1 1/4885EIF4A2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.